Interleukin (IL)-17, includes six subtypes such as IL-17A and IL-17F, plays an important role in the pathogenesis of a variety of immune-mediated diseases. The currently marketed IL-17A inhibitors have good effects on psoriasis, psoriatic arthritis and ankylosing spondylitis. Bimekizumab (UCB4940) is a noval humanized monoclonal immunoglobulin G1 antibody developed by Belgium's Utimes Company, which is designed to selectively bind to specific sites on IL-17A and IL-17F, and simultaneously inhibiting both IL-17A and IL17F, thereby producing a stronger anti-inflammatory effect than inhibiting IL-17A alone. The latest phase Ⅲ clinical study data show that bimekizumab is effective in treating psoriasis and is well tolerated. This article reviewed the pharmacology, pharmacokinetics, clinical efficacy evaluation and safety of bimekizumab.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |